Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry)

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

(2017) Sébastien Le Burel et al.   EUROPEAN JOURNAL OF CANCER

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms

(2017) Danae A Delivanis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Biologic Disease-modifying Antirheumatic Drug (bDMARD)-induced Neutropenia: A Registry from a Retrospective Cohort of Patients with Rheumatic Diseases Treated with 3 Classes of Intravenous bDMARD

(2017) Francisco Espinoza et al.   JOURNAL OF RHEUMATOLOGY

Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer

(2017) Terufumi Kato et al.   LUNG CANCER

Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Patients

(2017) Vanesa Calvo-Río et al.   Arthritis & Rheumatology

Masterful Antibodies: Checkpoint Blockade

(2017) Nils Lonberg et al.   Cancer Immunology Research

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy

(2017) Vivek Kumar et al.   Frontiers in Pharmacology

Outcome of tocilizumab treatment in refractory ocular inflammatory diseases

(2016) Sukhum Silpa-archa et al.   ACTA OPHTHALMOLOGICA

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

(2016) Gerd R Burmester et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study

(2016) Valérie Devauchelle-Pensec et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting

(2016) Beatriz Guglieri-López et al.   ANTI-CANCER DRUGS

Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study

(2016) Ralf Gold et al.   BMC Neurology

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course

(2016) M. Nishino et al.   CLINICAL CANCER RESEARCH

Late-onset adverse events after a single dose of rituximab in children with complicated steroid-dependent nephrotic syndrome

(2016) Shuichiro Fujinaga et al.   CLINICAL NEPHROLOGY

Inflammatory Bowel Disease Provoked by Etanercept: Report of 443 Possible Cases Combined from an IBD Referral Center and the FDA

(2016) Aoibhlinn O’Toole et al.   DIGESTIVE DISEASES AND SCIENCES

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy

(2016) Lars Hofmann et al.   EUROPEAN JOURNAL OF CANCER

Incidence, Clinical Characteristics, and Management of Psoriasis Induced by Anti-TNF Therapy in Patients with Inflammatory Bowel Disease

(2016) Iván Guerra et al.   INFLAMMATORY BOWEL DISEASES

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102)

(2016) Yuji Miyamoto et al.   International Journal of Clinical Oncology

Tocilizumab-induced pancreatitis: case report and review of data from the FDA Adverse Event Reporting System

(2016) T. Flaig et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort

(2016) Shelley Ji Eun Hwang et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

(2016) Padmanee Sharma et al.   LANCET ONCOLOGY

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Immune-related pancreatitis secondary to nivolumab in a patient with recurrent lung adenocarcinoma: A case report

(2016) Kazuhiko Ikeuchi et al.   LUNG CANCER

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels

(2016) Marijana Protic et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Infliximab-induced skin manifestations in patients with inflammatory bowel disease

(2016) Alec Eligius Hellström et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Doubling the single-dose infusion rate of tocilizumab in rheumatoid arthritis is safe and efficacious

(2016) HM Lindegaard et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Late-onset neutropenia after rituximab in ANCA-associated vasculitis

(2016) A Knight et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Efficacy and safety of re-induction therapy with bevacizumab and paclitaxel for metastatic breast cancer

(2016) Tetsuhiro Yoshinami et al.   Breast Cancer

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders

(2016) Douglas B. Johnson et al.   JAMA Oncology

Cumulative Incidence of, Risk Factors for and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience

(2015) Estelle Fréling et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Characteristics of Skin Lesions Associated With Anti–Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease

(2015) Isabelle Cleynen et al.   ANNALS OF INTERNAL MEDICINE

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer

(2015) E. M. Dijkgraaf et al.   ANNALS OF ONCOLOGY

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)

(2015) Jens Klotsche et al.   ANNALS OF THE RHEUMATIC DISEASES

Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

(2015) Yoshinori Munemoto et al.   BMC CANCER

Ustekinumab-induced drug eruption resembling lymphocytic infiltration (of Jessner-Kanof) and lupus erythematosus tumidus

(2015) Claudio Guarneri et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001)

(2015) Wei Ou et al.   CANCER

Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma

(2015) David Aguiar-Bujanda et al.   Clinical Lymphoma Myeloma & Leukemia

Pancreatitis Secondary to Anti–Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT

(2015) Yazan Z. Alabed et al.   CLINICAL NUCLEAR MEDICINE

Psoriasiform Skin Lesions Are Caused by Anti-TNF Agents Used for the Treatment of Inflammatory Bowel Disease

(2015) Lauren A. George et al.   DIGESTIVE DISEASES AND SCIENCES

Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort

(2015) A. Mallett et al.   INTERNAL MEDICINE JOURNAL

A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)

(2015) Yutaka Ogata et al.   International Journal of Clinical Oncology

Phase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer

(2015) Hidehito Horinouchi et al.   INVESTIGATIONAL NEW DRUGS

Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics

(2015) D. Barthel et al.   JOURNAL OF RHEUMATOLOGY

Anti-TNF alpha medications and neuropathy

(2015) Pinelopi Tsouni et al.   JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

(2015) Antoni Ribas et al.   LANCET ONCOLOGY

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

(2015) Jeffrey S Weber et al.   LANCET ONCOLOGY

Efficacy of Anakinra in Refractory Adult-Onset Stillʼs Disease

(2015) Francisco Ortiz-Sanjuán et al.   MEDICINE

Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis

(2015) Javier Narváez et al.   PLoS One

Anakinra for the treatment of acute severe gout in critically ill patients

(2015) Jessica T. Thueringer et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

(2015) Javier Loricera et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Lessons Learned From the Clinical Trials of Novel Biologics and Small Molecules in Lupus Nephritis

(2015) Richard Furie et al.   SEMINARS IN NEPHROLOGY

Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry

(2015) Ivan Foeldvari et al.   ARTHRITIS CARE & RESEARCH

Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder

(2015) Marius Ringelstein et al.   JAMA Neurology

What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort

(2014) K Takase et al.   ANNALS OF THE RHEUMATIC DISEASES

Traitement par tocilizumab : expérience d’un centre de rhumatologie pédiatrique

(2014) C. Le Stradic et al.   ARCHIVES DE PEDIATRIE

Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: A french multicenter study

(2014) Antoine Néel et al.   AUTOIMMUNITY REVIEWS

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

(2014) David S. Hong et al.   CANCER

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

(2014) Devalingam Mahalingam et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study

(2014) L. Min et al.   CLINICAL CANCER RESEARCH

Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer

(2014) Bert H. O'Neil et al.   Clinical Colorectal Cancer

Long-Term Maintenance Therapy Using Rituximab-Induced Continuous B-Cell Depletion in Patients with ANCA Vasculitis

(2014) W. F. Pendergraft et al.   Clinical Journal of the American Society of Nephrology

Etanercept and uveitis: friends or foes?

(2014) Pilar Brito-Zerón et al.   CURRENT MEDICAL RESEARCH AND OPINION

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

(2014) Mabel Ryder et al.   ENDOCRINE-RELATED CANCER

Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma

(2014) Yasuyuki Arai et al.   Hematology

Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma

(2014) Alexander T. Faje et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Rituximab Extended Schedule or Re-Treatment Trial for Low–Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402

(2014) Brad S. Kahl et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort

(2014) Yazmin Odia et al.   JOURNAL OF NEURO-ONCOLOGY

Late-onset Neutropenia in Patients with Rheumatoid Arthritis after Treatment with Rituximab

(2014) R. Abdulkader et al.   JOURNAL OF RHEUMATOLOGY

NCCTG N0821 (Alliance): A Phase II First-Line Study of Pemetrexed, Carboplatin, and Bevacizumab in Elderly Patients with Advanced Nonsquamous Non–Small-Cell Lung Cancer With Good Performance Status

(2014) Grace K. Dy et al.   Journal of Thoracic Oncology

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study

(2014) Pippa G Corrie et al.   LANCET ONCOLOGY

Incidence of pneumonitis in patients with non-Hodgkin lymphoma receiving chemoimmunotherapy with rituximab

(2014) Giselle Salmasi et al.   LEUKEMIA & LYMPHOMA

The therapeutic monoclonal antibody market

(2014) Dawn M Ecker et al.   mAbs

Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases

(2014) Ryuji Nagamine et al.   Modern Rheumatology

Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients

(2014) Ediz Dalkilic et al.   Modern Rheumatology

Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature

(2014) K. Kamei et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide

(2014) Thomas JA Lehman et al.   Pediatric Rheumatology

Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting

(2014) Maarit Tarkiainen et al.   RHEUMATOLOGY

Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study

(2014) Evripidis Kaltsonoudis et al.   ARTHRITIS RESEARCH & THERAPY

Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis

(2014) T. Nakashita et al.   BMJ Open

Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System

(2013) P. Deepak et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Repeated radioimmunotherapy with 131I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-Hodgkin lymphoma

(2013) Hye Jin Kang et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

(2013) Antonio Gonzalez-Martin et al.   EUROPEAN JOURNAL OF CANCER

Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment

(2013) Cornelia Tillack et al.   GUT

Tumor Necrosis Factor α Antagonist–associated Psoriasis in Inflammatory Diseases

(2013) Kevin E. Kip et al.   INFLAMMATORY BOWEL DISEASES

Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis

(2013) Daniel Wendling et al.   JOINT BONE SPINE

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2013) Bruce E. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Tolerability of one hour 10mg/kg infliximab infusions in inflammatory bowel diseases: A prospective multicenter cohort study

(2013) Abdenour Babouri et al.   Journal of Crohns & Colitis

The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: A single academic center case series

(2013) Anita Afzali et al.   Journal of Crohns & Colitis

Disrupting Cytokine Signaling in Pancreatic Cancer

(2013) Christina Wu et al.   PANCREAS

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

(2013) Caroline J. Voskens et al.   PLoS One

Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation — Single-center study

(2013) Hideki Ishida et al.   TRANSPLANT IMMUNOLOGY

A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer

(2012) Yong Sang Hong et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Low-dose alemtuzumab-associated immune thrombocytopenia in chronic lymphocytic leukemia

(2012) Gianluigi Reda et al.   AMERICAN JOURNAL OF HEMATOLOGY

Initiation of Anti-TNF Therapy and the Risk of Optic Neuritis: From the Safety Assessment of Biologic ThERapy (SABER) Study

(2012) Kevin L. Winthrop et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors

(2012) Gordana Vlahovic et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Biologics-induced autoimmune diseases

(2012) Roberto Perez-Alvarez et al.   CURRENT OPINION IN RHEUMATOLOGY

Rituximab-induced thrombocytopenia: a cohort study

(2012) Thijs J. Giezen et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

(2012) Luis Leon et al.   EXPERT OPINION ON PHARMACOTHERAPY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of New-onset and Flare of Preexisting Psoriasis During Rituximab Therapy for Rheumatoid Arthritis: Data from the French AIR Registry

(2012) L. THOMAS et al.   JOURNAL OF RHEUMATOLOGY

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Alfons JM van den Eertwegh et al.   LANCET ONCOLOGY

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Ravi A Madan et al.   LANCET ONCOLOGY

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

(2012) Anna Maria Di Giacomo et al.   LANCET ONCOLOGY

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

(2012) Kim Margolin et al.   LANCET ONCOLOGY

Late-onset neutropenia following primary treatment of diff use large B-cell lymphoma with rituximab-containing therapy

(2012) Samo Rozman et al.   LEUKEMIA & LYMPHOMA

Vasculitis Associated With Tumor Necrosis Factor-α Inhibitors

(2012) Olayemi Sokumbi et al.   MAYO CLINIC PROCEEDINGS

Severe haematological complications during treatment with natalizumab

(2012) L Midaglia et al.   Multiple Sclerosis Journal

Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis

(2012) Fabrizio De Benedetti et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches

(2012) Osamu Matsuno   RESPIRATORY RESEARCH

Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

(2012) S. Unizony et al.   ARTHRITIS CARE & RESEARCH

Who Dies from Sarcoidosis and Why?

(2011) Robert P. Baughman et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma

(2011) Yu-Chung Huang et al.   ANNALS OF HEMATOLOGY

Late-onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infections

(2011) Daniel Tesfa et al.   ARTHRITIS AND RHEUMATISM

A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis

(2011) A. Cuker et al.   BLOOD

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy

(2011) Riccardo Danielli et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Skin Manifestations Induced by TNF-Alpha Inhibitors in Juvenile Idiopathic Arthritis

(2011) Irene Pontikaki et al.   CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY

Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: Experience from a consecutive cohort of inflammatory bowel disease patients

(2011) Daniel C. Baumgart et al.   INFLAMMATORY BOWEL DISEASES

Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: A report of 21 cases

(2011) Iván Guerra et al.   Journal of Crohns & Colitis

Short-term study of infliximab treatment for Crohn's disease in China

(2011) Jia Ju ZHENG et al.   Journal of Digestive Diseases

Anti-nuclear antibody positivity and the use of certolizumab in inflammatory bowel disease patients who have had arthralgias or lupus-like reactions from infliximab or adalimumab

(2011) Himanshu Dev VERMA et al.   Journal of Digestive Diseases

Development of Inflammatory Bowel Disease in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

(2011) T. D. van DIJKEN et al.   JOURNAL OF RHEUMATOLOGY

A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

(2011) David R. Spigel et al.   Journal of Thoracic Oncology

Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort

(2011) M. Cossburn et al.   NEUROLOGY

Non-infectious pulmonary toxicity of rituximab: a systematic review

(2011) A. V. Hadjinicolaou et al.   RHEUMATOLOGY

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review

(2011) A. V. Hadjinicolaou et al.   RHEUMATOLOGY

Randomized Trial of Dual Antibody Induction Therapy With Steroid Avoidance in Renal Transplantation

(2011) Gaetano Ciancio et al.   TRANSPLANTATION

Rituximab-induced late onset neutropenia in newly-diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism

(2010) Szu-Chin Li et al.   AMERICAN JOURNAL OF HEMATOLOGY

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Rituximab Administration within 6 Months of T Cell-Depleted Allogeneic SCT is Associated with Prolonged Life-Threatening Cytopenias

(2010) Zachariah McIver et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)

(2010) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

(2010) J. M. Kirkwood et al.   CLINICAL CANCER RESEARCH

Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma

(2010) C. Ralph et al.   CLINICAL CANCER RESEARCH

Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Single-Institution Experience

(2010) Binu Malhotra et al.   Clinical Lung Cancer

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

(2010) Mariangela Atteno et al.   CLINICAL RHEUMATOLOGY

Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease

(2010) Florian Beigel et al.   INFLAMMATORY BOWEL DISEASES

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

(2010) Evan M. Hersh et al.   INVESTIGATIONAL NEW DRUGS

Is the family history positive for SLE a predisposing factor for anti-TNFalpha blockers induced lupus? A case report

(2010) Paola Caramaschi et al.   JOINT BONE SPINE

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor necrosis factor antagonist-associated neutropenia: Comment on the article by Hastings et al

(2010) Spyros Aslanidis et al.   ARTHRITIS CARE & RESEARCH

Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma

(2009) Gillianne Geet Yi Lai et al.   AMERICAN JOURNAL OF HEMATOLOGY

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis

(2009) Rachel B. Jones et al.   ARTHRITIS AND RHEUMATISM

Autoimmune diseases induced by biological agents

(2009) Manuel Ramos-Casals et al.   AUTOIMMUNITY REVIEWS

Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF

(2009) L. Fong et al.   CANCER RESEARCH

Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

(2009) S. M. Ansell et al.   CLINICAL CANCER RESEARCH

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

(2009) J. Weber et al.   CLINICAL CANCER RESEARCH

Medikamenteninduzierter Lupus erythematodes tumidus unter Adalimumab-Therapie

(2009) S. Sohl et al.   HAUTARZT

Adalimumab safety in global clinical trials of patients with Crohnʼs disease

(2009) Jean-Frédéric Colombel et al.   INFLAMMATORY BOWEL DISEASES

Late Onset Neutropenia and Immunoglobulin Suppression of the Patients with Malignant Lymphoma Following Autologous Stem Cell Transplantation with Rituximab

(2009) Yasuo Hirayama et al.   INTERNAL MEDICINE

Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer

(2009) Jyoti D. Patel et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma

(2009) Luis H. Camacho et al.   JOURNAL OF CLINICAL ONCOLOGY

Postmarketing Surveillance of the Safety and Effectiveness of Etanercept in Japan

(2009) T. KOIKE et al.   JOURNAL OF RHEUMATOLOGY

Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study

(2009) D. Fouache et al.   RHEUMATOLOGY

Immune-mediated skin lesions in patients treated with anti-tumour necrosis factor alpha inhibitors

(2009) SA Exarchou et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Vasculitis induced by tumor necrosis factor-targeted therapies

(2009) Manuel Ramos-Casals et al.   Current Rheumatology Reports

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES

Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor   therapy: results from the British Society for Rheumatology Biologics Register

(2008) M J Harrison et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Uveitis following the use of tumor necrosis factor α inhibitors: Comment on the article by Lim et al

(2008) Rossana Scrivo et al.   ARTHRITIS AND RHEUMATISM

Autoimmune diseases induced by TNF-targeted therapies

(2008) Manuel Ramos-Casals et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis

(2008) M. E. Perry et al.   CLINICAL RHEUMATOLOGY

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

(2008) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET

Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia

(2008) K Stamatopoulos et al.   LEUKEMIA

Late-onset neutropenia associated with rituximab therapy: evidence for a maturation arrest at the (pro)myelocyte stage of granulopoiesis

(2008) Daniel Tesfa et al.   MEDICAL ONCOLOGY

Focus on adverse events of tumour necrosis factor   blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients

(2007) V Gerloni et al.   ANNALS OF THE RHEUMATIC DISEASES